NCT01706692Recruiting
Swiss Dermatology Network of Targeted Therapies (SDNTT)
Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics
Source: ClinicalTrials.gov · Last updated 29 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy. The registry will also evaluate safety clinical outcomes and health related quality of life.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1121 (estimated)
- First submitted
- 19 Sept 2012
- Start date
- Feb 2011
- Primary completion date
- 15 Mar 2032
- Lead sponsor
- Swiss Dermatology Network for Targeted Therapies
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT01706692
What you commit to
- Study type: Observational
- Planned participants: 1121
- From Feb 2011 to the primary completion date, 15 Mar 2032
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Lack of informed consent
- Patients being participants of clinical trials at the day of registration to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analyzed separately)
Who the study is looking for
- Patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist,
- age ≥ 18,
- Being administered a specific biologic/conventional systemic drug for the first time
- Sufficient language skills (German, French, Italian and English) for the informed consent to participate
- Informed consent to participate
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarau Cantonal Hospital Coordinator of this site? Confirm its status | Aarau | Switzerland | Recruiting |
| Basel University Hospital Coordinator of this site? Confirm its status | Basel | Switzerland | Recruiting |
| Inselspital, Bern University Hospital Coordinator of this site? Confirm its status | Bern | Switzerland | Recruiting |
| Centre Hospitalier Universitaire Vaudois (CHUV) Coordinator of this site? Confirm its status | Lausanne | Switzerland | Recruiting |
| St. Gallen Cantonal Hospital Coordinator of this site? Confirm its status | Sankt Gallen | Switzerland | Recruiting |
| Zurich University Hospital Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.